Mar. 18 at 8:23 PM
$SERA
🚨
In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women, was published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine. Key findings from the Study include:
56% and 32% fewer babies were born before 32 and 35 weeks, respectively
20% fewer babies admitted to the NICU
Fewer health complications for newborns (20% reduction in odds of neonatal morbidity)
A NICU day was saved for every 4.2 patients screened
Advanced discussions underway with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption, including the addition of a new partner program, bringing the total to two active partner programs.
"2025 marked a pivotal year for Sera as we moved from clinical validation to commercial execution," said Zhenya Lindgardt, Sera's President and Chief Executive Officer.
